← Leaderboards
Kevin Ron Nash
University Of South Florida
$4,031,811
Attributed
$6,973,133
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,973,133 · 5
By mechanism
R01$3,390,783 · 1
R44$2,491,861 · 1
R21$1,090,489 · 3
Top collaborators
- Layton Harris Smith3 shared
- Steven H Olson2 shared
- Satheesh B Ravula2 shared
Most similar at University Of South Florida
Same institution · by research overlap
- John Adams$29,453,928
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposMouse ModelIn VivoAnimal ModelPathologyBrainProteinsNeuronsBiochemicalS DiseaseMolecularNovel TherapeuticsSmall MoleculeLeadReceptorDrug DiscoveryAutopsyRodentPharmaceutical PreparationsEnsurePropertyAnimalsNerve DegenerationDose
Grant awards (11)
Reelin and Fragile X Syndrome$187,500
R21 · FY2025 · NS · contact PI
Targeting neuroinflammation in AD with novel CX3CR1 agonists$554,644
R01 · FY2023 · AG
Targeting neuroinflammation in AD with novel CX3CR1 agonists$562,501
R01 · FY2022 · AG
Targeting neuroinflammation in AD with novel CX3CR1 agonists$677,072
R01 · FY2021 · AG
Gene Therapy Rescue of Angelman Syndrome with Reelin$411,125
R21 · FY2021 · NS · contact PI
Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease$1,322,759
R44 · FY2020 · AG
Targeting neuroinflammation in AD with novel CX3CR1 agonists$791,283
R01 · FY2020 · AG
Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease$1,169,102
R44 · FY2019 · AG
Targeting neuroinflammation in AD with novel CX3CR1 agonists$805,283
R01 · FY2019 · AG
Therapeutic Agonist of CX3CR1 for Alzheimer's Disease$220,859
R21 · FY2019 · AG · contact PI
Therapeutic Agonist of CX3CR1 for Alzheimer's Disease$271,005
R21 · FY2018 · AG · contact PI